About Thyroxine-binding globulin
Thyroxine-binding globulin (SERPINA7) is a protein
from Homo sapiens identified by UniProt accession
P05543, 415 residues long.
MolForge cross-references it against 0 known binders and
157 disease associations.
Target properties
| Protein name | Thyroxine-binding globulin |
|---|
| UniProt accession | P05543 |
|---|
| Gene | SERPINA7 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 415 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (157)
Diseases linked to this target (Open Targets).
- thyroxine-binding globulin measurement · score 0.53
- neoplasm · score 0.10
- hyperinsulinemic hypoglycemia, familial, 4 · score 0.07
- Pallister-Hall syndrome · score 0.05
- colorectal cancer · score 0.04
- hepatocellular carcinoma · score 0.04
- non-alcoholic steatohepatitis · score 0.04
- thyroxine measurement · score 0.03
- infection · score 0.02
- infect · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P05543-F1 | alphafold | PREDICTED | 87.05 | — |
Amino-acid sequence (415 residues)
MSPFLYLVLL VLGLHATIHC ASPEGKVTAC HSSQPNATLY KMSSINADFA FNLYRRFTVE TPDKNIFFSP VSISAALVML SFGACCSTQT EIVETLGFNL TDTPMVEIQH GFQHLICSLN FPKKELELQI GNALFIGKHL KPLAKFLNDV KTLYETEVFS TDFSNISAAK QEINSHVEMQ TKGKVVGLIQ DLKPNTIMVL VNYIHFKAQW ANPFDPSKTE DSSSFLIDKT TTVQVPMMHQ MEQYYHLVDM ELNCTVLQMD YSKNALALFV LPKEGQMESV EAAMSSKTLK KWNRLLQKGW VDLFVPKFSI SATYDLGATL LKMGIQHAYS ENADFSGLTE DNGLKLSNAA HKAVLHIGEK GTEAAAVPEV ELSDQPENTF LHPIIQIDRS FMLLILERST RSILFLGKVV NPTEA
Explore Thyroxine-binding globulin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets